Gendered perceptions of new mobility services

Transport systems´ infrastructure and provided services affect people´s mode choices and define the users´ transport experience. This study focuses on the exploration of how perceptions of existing and new transport services vary among men and women and which potential measures can improve the users´ experiences. A survey is designed and replies from 1193 citizens of three European cities is collected. The data analysis aimed to indicate in which areas the perceptions of men and women differ. The results indicated that men have more trust in new technologies that can be used in mobility services such as autonomous vehicles while women have a positive attitude towards the inclusions of measures that can enhance security in the passenger experience, especially in the public transport sector.info:eu-repo/semantics/publishedVersio

A preliminary analysis on gender aspects in transport systems and mobility services: presentation of a survey design

As sustainability is becoming a common practice in planning transport systems and mobility services, the designation and management of gender issues are of paramount importance. TInnGO is a European Project that has developed a network of 10 national Hubs to build the capacity to generate and apply evidence on gender equality and transport issues at the European level. This paper presents the project activities by introducing a relevant framework and exploring user mobility experiences based on gender to identify diversified needs and requirements. This process relies on the combination of a review of current gender-oriented experiences and practices in mobility with focus group activities conducted in four different EU cities. The insights obtained from these activities supported the design of a survey to collect information on socioeconomic, personal, and operational aspects to serve a gender-oriented transport analysis for all the Hubs. These preliminary analyses identified the main issues related to the female mobility experience, namely safety, security, accessibility, and transport reliability. Future research on the data collected through the survey would help operators in successfully improving their mobility offer to women.info:eu-repo/semantics/publishedVersio

Assessment of the perceived security among public transport users in Europe

Passenger experiences with public transport are expected to be safe, secure, comfortable, convenient and pleasant. However, this experience is often disrupted by harassment incidents, such as sexual, theft and verbal harassment that may affect passengers' perspective towards public transport services. Security perceptions and harassment experiences may vary according to gender and age. This study analyses the perceptions of 2413 citizens in six European cities over security aspects of public transport and potential measures that can improve these perceptions. Harassment experiences are also illustrated, and their patterns are discussed. The paper concludes with some recommendations to operators of public transport over enhancing the feeling of security and ameliorating negative experiences related to harassment.info:eu-repo/semantics/publishedVersio

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

[This corrects the article DOI: 10.1038/s41523-018-0074-6.]

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Advances in the surgical management of the axilla in patients treated with neoadjuvant chemotherapy, especially those with node positive disease at diagnosis, have led to changes in practice and more judicious use of axillary lymph node dissection that may minimize morbidity from surgery. However, there is still significant confusion about how to optimally manage the axilla, resulting in variation among practices. From the viewpoint of drug development, assessment of response to neoadjuvant chemotherapy remains paramount and appropriate assessment of residual disease-the primary endpoint of many drug therapy trials in the neoadjuvant setting-is critical. Therefore decreasing the variability, especially in a multicenter clinical trial setting, and establishing a minimum standard to ensure consistency in clinical trial data, without mandating axillary lymph node dissection, for all patients is necessary. The key elements which include proper staging and identification of nodal involvement at diagnosis, and appropriately targeted management of the axilla at the time of surgical resection are presented. The following protocols have been adopted as standard procedure by the I-SPY2 trial for management of axilla in patients with node positive disease, and present a framework for prospective clinical trials and practice

Sacituzumab govitecan in metastatic triple-negative breast cancer

BACKGROUND: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker. METHODS In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-negative breast cancer. The primary end point was progression-free survival (as determined by blinded independent central review) among patients without brain metastases. RESULTS A total of 468 patients without brain metastases were randomly assigned to receive sacituzumab govitecan (235 patients) or chemotherapy (233 patients). The median age was 54 years; all the patients had previous use of taxanes. The median progression-free survival was 5.6 months (95% confidence interval [CI], 4.3 to 6.3; 166 events) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.6; 150 events) with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 0.32 to 0.52; P<0.001). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95% CI, 0.38 to 0.59; P<0.001). The percentage of patients with an objective response was 35% with sacituzumab govitecan and 5% with chemotherapy. The incidences of key treatment-related adverse events of grade 3 or higher were neutropenia (51% with sacituzumab govitecan and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and <1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). There were three deaths owing to adverse events in each group; no deaths were considered to be related to sacituzumab govitecan treatment. CONCLUSIONS Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan